NCT04650451View on ClinicalTrials.gov

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

PHASE1SuspendedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

January 2, 2027

Conditions
HER-2 Gene AmplificationHER2-positive Gastric CancerHER2-positive Breast CancerHER-2 Protein OverexpressionSolid Tumor, Adult
Interventions
BIOLOGICAL

chimeric antigen receptor (CAR) T cell therapy

HER2-targeted dual-switch CAR-T cells

Trial Locations (7)

14263

Roswell Park Cancer Institute, Buffalo

60637

University of Chicago, Chicago

77030

The University of Texas MD Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

92093

University of California San Diego (UCSD), La Jolla

322972

Winship Cancer Institute at Emory University, Atlanta

07601

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
lead

Bellicum Pharmaceuticals

INDUSTRY